Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

Allergic Bronchopulmonary Aspergilloses Clinical Trial

— ABPA-MR  

Official title:

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03265366
• Other study ID #: CHUBX 2016/12
• Status: Completed
• Phase: N/A
• Start date: September 14, 2017
• Est. completion date: January 24, 2020

Study information

• Verified date: February 2022
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).

Description:

The ABPA is responsible for pulmonary exacerbations in chronic bronchial diseases. The treatment of ABPA consists in systemic corticosteroids and anti fungal therapy, which can have severe side effects. The diagnosis is difficult, based on several but non-specific characteristics. One of the radiologic abnormalities on CTscan could be more specific : high attenuation in impacted mucus, but this sign is found in about 30% of cases. Recent articles and investigators experience seem to demonstrate that MRI could provide an interesting tool for ABPA diagnosis, studying the signal of bronchial impactions. The aim of the study is to describe the MRI characteristics of patients with ABPA and compare the results with those obtained by CTscan, and in order to determine if there is a specific signal of impaction in ABPA.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: January 24, 2020
• Est. primary completion date: January 24, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• study patients have a diagnosis of ABPA
• control patients have severe asthma
• All the patients are = 18 years old, have social security care, signature of consent form

Exclusion Criteria:

• cystic fibrosis
• other type of aspergilloses
• contraindication for MRI
• woman without effective contraception

Related Conditions & MeSH terms

• Allergic Bronchopulmonary Aspergilloses
• Aspergillosis
• Pulmonary Aspergillosis

Intervention

Device:
• MRI
It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
• CT scan (standard reference)
It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

Locations

Country	Name	City	State
France	CHU de Bordeaux	Pessac

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions)	Measured by a kappa test	Day 0